Biggest stock movers today: RH, AKBA, and more [Seeking Alpha]
Akebia Therapeutics, Inc. (AKBA)
Last akebia therapeutics, inc. earnings: 3/10 07:49 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.akebia.com/investor-relations
Company Research
Source: Seeking Alpha
Here are some of Thursday's biggest stock movers: Biggest stock gainers Despite missing market expectations in Q4, RH ( RH shares rose 8% on the prospect of improved performance in the home furnishing business. Demand in Q1 is expected to grow in the positive mid-single digits, while revenue is anticipated to decline in the low single digits. Adjusted operating margin is targeted to be 6%–7%, and adjusted EBITDA is 12%–13%. For FY2024, demand is forecast to grow 12%–14%, with revenue increasing by 8%–10%. Adjusted operating margin is expected to be 13%–14%, and adjusted EBITDA margin is expected to be 12%–13%. Shares of Akebia Therapeutics ( AKBA surged 25% following the FDA's approval of Vafseo ® (vadadustat) Tablets for the treatment of anemia due to chronic kidney disease (CKD) in adults on dialysis for at least three months. Vafseo is a once-daily oral medication that stimulates the body's production of erythropoietin to manage anemia. The approval, based on data from the I
Show less
Read more
Impact Snapshot
Event Time:
AKBA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AKBA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AKBA alerts
High impacting Akebia Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AKBA
News
- Akebia Therapeutics to Report First Quarter 2024 Financial Results and Discuss Recent Business HighlightsPR Newswire
- Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR Newswire
- Akebia Therapeutics, Inc. (NASDAQ: AKBA) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.MarketBeat
- When Can We Expect A Profit From Akebia Therapeutics, Inc. (NASDAQ:AKBA)? [Yahoo! Finance]Yahoo! Finance
- AVEROA Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of AVA1014 for Treating Complications Associated with Chronic Kidney Disease [Yahoo! Finance]Yahoo! Finance
AKBA
Earnings
- 3/14/24 - Beat
AKBA
Sec Filings
- 4/25/24 - Form ARS
- 4/25/24 - Form DEFA14A
- 4/25/24 - Form DEF
- AKBA's page on the SEC website